Veradermics (MANE) EPS (Basic) (2025 - 2026)
Veradermics' (MANE) quarterly EPS (Basic) came in at -$1.32 in Q1 2026, up 93.32% YoY from -$0.68 in Q1 2025, and up 93.32% on a QoQ basis from -$19.79 in Q1 2025.
Veradermics (MANE) EPS (Basic) (2025 - 2026) Analysis & Trends
Veradermics (MANE) has 2 years of EPS (Basic) data on file, last reported at -$1.32 in Q1 2026.
- Quarterly EPS (Basic) rose 93.32% year-over-year to -$1.32 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.96 (changed N/A YoY) and the FY2025 annual result came in at -$111.91, down 202.06% from the prior year.
- EPS (Basic) improved to -$1.32 in Q1 2026, from -$19.79 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$1.32 in Q1 2026 to a low of -$19.79 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 7.59 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.06 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.16 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.18 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.23 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.06 |
| 10 | Veradermics | 4.70 Bn | 4.70 Bn | - | -0.58 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.58 |
| Mar 31, 2026 | -1.32 |
| Mar 31, 2025 | -19.79 |